BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 20, 2016
View Archived Issues
GnHR antagonist SKI-2670 well tolerated, suppresses hormones in phase I trial
Read More
Sirenas enters drug discovery collaboration with Calibr
Read More
U.K. Dstl gets funding to study inhaled ciprofloxacin in biodefense
Read More
Two mutations at the same anticodon stem pair may cause different myopathic phenotypes
Read More
Hookipa Biotech presents data on CMV vaccine candidate
Read More
PSMA ligand [99mTc]MIP-1427 improves diagnostics in osseous metastasized prostate cancer
Read More
Argonaut Therapeutics raises funds to develop cancer drugs
Read More
Advanced Proteome Therapeutics acquires option to antibody candidates from University of Toronto
Read More
Pfizer wins grant from Bill & Melinda Gates Foundation for GBS vaccine trial
Read More
Omeros reports results from phase II study of PPARgamma agonist in cocaine use disorder
Read More
Merck & Co. patents TrK-A inhibitors
Read More
Shionogi discloses ACC2 inhibitors
Read More
FDA grants accelerated approval for Lartruvo in soft tissue sarcoma
Read More
Takeda Pharmaceutical describes ACC1 inhibitors
Read More
Fujifilm Kyowa Kirin Biologics reports phase III results for adalimumab biosimilar FKB-327
Read More
Spotlight Innovation obtains exclusive worldwide license for STL-182
Read More
ICGEB and Sun Pharma collaborate on new tetravalent dengue vaccine
Read More
Pivotal phase III study of letermovir meets primary endpoint
Read More
Texas A&M University develops pateamine A analogues
Read More
Incyte presents LSD1 inhibitors
Read More
MHRA accepts XOMA's proposal for phase II study of XOMA-358 in congenital hyperinsulinism
Read More
Cerulean collaborates with Novartis to develop nanoparticle-drug conjugate product candidates
Read More
Rare SHANK3 mutation may be a risk factor for ASD and schizophrenia
Read More
Applied Genetic Technologies files IND for second achromatopsia therapeutic candidate
Read More
Australian NHMRC funds research in chronic lung diseases
Read More
Perlara forms drug discovery collaboration with Novartis
Read More